» Download Public Reports
8 reports
- Company report
- November 2012
- 3 pages
... Represented by its new brand boehringer ingelheim bioxcellence . As a leading biopharmaceutical contract manufactu with more than 35 years of experience The company has brought 19 biopharmaceutical ...
October 2011
... European mab biosimilar guideline overcome the unique manufacturing challenges facing the development of novel therapies such as bi-specifics, antibody fragments, combination antibodies and adcs find novel ...
June 2011
... Ingelheim has brought 17 molecules to market and has many years of experience in multiple molecule classes such as monoclonal antibodies, recombinant proteins, interferons, enzymes, fusion molecules ...
March 2011
... Up on an european vaccine agenda (eu research valorisation) Network with other stakeholders such as dcvmn Synergy with private sector Global collaboration 6 evolution of evi Malaria focus Product focus ...
April 2010
... As vaccines, successful in clinical phase ii. Direct technological competitor to redbiotec 16business summary redbiotec. Medicago, ligocyte, selectvaccines vaccine companies with different approaches to vlp ...
April 2010
... Communication Representation International affairs Public affairs regulatory issues nutrition next generation antibodies nanotech white biotech sibc Biokatalyse kons. Sgci bioactors Jobs sls marketing ...
February 2009
... Be manipulated to produce highly specific versions of a given antibody that have a better circulatory half-life, targeted tissue distribution and/or increased potency than the originals. Moreover, the yeast ...
June 2008
... To produce protein products effectively, where the industry has struggled to date with low yields and unstable platforms. This record surpasses all other production systems including those previously set ...